Vimarsana
Biggest News Aggregation in the World

Page 26 - Roivant Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Roivant Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Roivant Sciences Today - Breaking & Trending Today

The presidential candidates: This week, Vivek Ramaswamy - Vimarsana News

The presidential candidates: This week, Vivek Ramaswamy

A profile of Republican presidential candidate Vivek Ramaswamy.

Roivant's Matt Gline on raising capital and biotech's outlook in 2024 - Vimarsana News

Roivant's Matt Gline on raising capital and biotech's outlook in 2024

BioPharma

5 Stocks Under $20 To Buy Now - Insider Monkey - Vimarsana News

5 Stocks Under $20 To Buy Now - Insider Monkey

New York-based Roivant Sciences Ltd. (NASDAQ:ROIV) is a commercial-stage biopharmaceutical company focused on accelerating the development and commercialization of medicines.

Lupus Drug Fails to Reduce Symptoms in Mid-stage Study - Vimarsana News

Lupus Drug Fails to Reduce Symptoms in Mid-stage Study

Roivant Sciences said on Monday its experimental drug to treat systemic lupus erythematosus failed to reduce symptoms of the autoimmune disease in a mid-stage study.

Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus - Vimarsana News

Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus

Oral brepocitinib failed to meet its primary endpoint of Systemic Lupus Erythematosus Responder Index change of 4 at Week 52Priovant plans to continue progressing the program in indications outside...